Press

Cybin Announces Scientific Presentation at the 5th Annual Neuropsychiatric & Psychedelics Drug Development Summit

Nov 1 • 3 min read

Cybin Inc. (NEO:CYBN | NYSE American:CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics®, today announced an upcoming presentation at the Neuropsychiatric & Psychedelics Drug Development Summit taking place October 31 to November 2, 2022, in Boston, MA. The presentation, titled “CYB004-Modifications to DMT to Enhance its Therapeutic Potential,” will highlight preclinical data for CYB004,…

PharmaTher Enters into Exclusive Option Agreement with Case Western Reserve University to Develop and Commercialize Ketamine for Rett Syndrome

Nov 1 • 4 min read

PharmaTher Holdings Ltd. (OTCQB: PHRRF | CSE: PHRM), a specialty pharmaceutical company focused on developing and commercializing novel uses and delivery forms of ketamine to treat mental health, neurological and pain disorders, is pleased to announce that the Company has entered into an evaluation and exclusive option agreement (the “Agreement”) with Case Western Reserve University…

Irwin Naturals Looks to Add to Florida Foothold, Expanding Chain of Healthcare Clinics

Nov 1 • 5 min read

Irwin Naturals Inc. (CSE: IWIN | OTC: IWINF | FRA: 97X) has reached a binding agreement to acquire Dura Medical, LLC, a clinic in Naples, Florida, which offers ketamine-infusion therapy among its options for cutting-edge treatment of mental health disorders. The clinic will be incorporated into Irwin Naturals Emergence, a fast-growing national chain offering psychedelic mental healthcare…

Apex Labs Granted Approval for North America’s First Take Home Psilocybin Clinical Trial

Nov 1 • 2 min read

Apex Labs Ltd., a pharmaceutical company optimizing the standard of mental health care for Veterans, is pleased to announce its approval for the first North American take home multi-dose psilocybin clinical trial, APEX-002-A01-02, evaluating the safety and efficacy of APEX-52 (psilocybin) in treating depression in Veterans with Post Traumatic Stress Disorder (“PTSD”). This approval comes by…

Numinus Re-Launches “Psychedelic Therapy Frontiers” Podcast with additional hosts and topics

Nov 1 • 5 min read

Numinus Wellness Inc. (TSX: NUMI | OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced the re-launch of “Psychedelic Therapy Frontiers,” a podcast series that will now be hosted by Numinus’ Clinical Director of Education and Training, Dr. Stephen Thayer, Chief Clinical Officer, Dr. Reid Robinson as well as Dr. Joe Flanders, Vice President of Psychology….

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441